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We present the case of a child with acute lymphoid leukemia (ALL) who was morphologically classified as FAB L1 (PAS and peroxi-
dase were negative). Remission was achieved with an ALL-type protocol (GBTLI). Five months after the discontinuation of therapy,
the patient presented mixed leukemia (C01O, C019, C013 and C033 were positive) with t (9;11) (p21 ;q23) translocation. Unfortu-
nately, as cytogenetic and immunophenotype studies were not performed at diagnosis, two possibilities could be considered for the
relapse; secondary mixed leukemia with clonal chromosome changes, or mixed leukemia from the beginning.
UNITERMOS: Leukemia, karyotipe. Epipodophillotoxin derivative.
CASE REPORT
An 8 year-old boy was first seen in August 1989with the following readings: Hg= 9.5g percent,WBC= I85,000/mm3 with 90 percent blasts and
platelet count= 30,000/mm3• A bone marrow aspiration
revealed lymphoblast replacements that were negative for
myeloperoxidase and PAS stains. No immunophenotyping
or cytogenetics was performed. The morphological
diagnosis of ALL, L1 by FAB criterial was made, and the
child was treated according to the ALL-85 protocol of the
Brazilian Cooperative Group for the Treatment of Acute
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Leukemia, which consists of: I) induction with Vincristine,
Dexamethasone, Daunomycin, L-asparaginase and
Cytosine Arabinoside; 2) intensification with Etoposide
(epipodophyllotoxin derivative) and Cytosine Arabinoside
and: 3) maintenance with a rotation of the following drug
pairs for 123 weeks: Dexamethasone and Etoposide;
Teniposide and Cytosine Arabinoside; and 6-
Mercaptopurine and Methotrexate. Central nervous system
prophylaxis consisted of cranial irradiation (24 Gy) and
tri p Ie intrathecal therapy. 2
Five months after treatment was completed, a
bone marrow relapse occurred. At that time, bone
marrow aspirate showed 80 percent myeloblasts.
Myeloperoxidase and Sudan Black B were negative,
PAS was 39 percent positive and diffusely granular,
alpha naphtyl acetate esterase was 55 percent positive
without being inhibited by NaF, and ASD esterase was
negative. The immunophenotype was determined on
bone marrow cells by performing the standard method
CHAUFFAILLE, M.L.L.F.; YAMAMOTO, M.; OOONE Fo, V. et al. - A t (9;11) translocation in
childhood acute mixed leukemia
Sao Paulo Medical Journal/RPM 114(2): 1127-1130,1996
1128
of indirect immunofluorescence4 using the following
panel of monoclonal antibodies with the respective
results: CD33 (My9) = 24 percent, CD 13 (My7) = 22
percent, CD 14 (My 4) <5 percent, CD 19 (B 4) = 35
percent, CD 10 (calla) = 37 percent, CD7 (leu 9) = 12
percent, CD41 (pltl) <2 percent, and sIg = 11 percent.
Results greater than 20 percent were considered
positive. In addition, stained immunophenotyping on
bone marrow smears was performed by the alkaline
phos phatase/anti -al kal ine phos ph atase tech n ique
(APAAP), confirming previous results of monoclonal
antibodies.6 Chromosome studies were performed on
bone marrow cells examined after 24 hours of
unstimulated culture at 37°C using standard
techniques. III The chromosomes were classified
according to ISCN.s Results were: 46,XY, t(9; 11)
(p21;q23) (14 cells)/45,XY, t(9;11) (p21;q23),-13 (6
cells)/ 46,XY (2 cells).
The patient was placed on a new therapeutic regimen,
once again achieving a complete remission that lasted for
5 months, when a marrow relapse occurred.
DISCUSSION
cytogenetically distinct from classical therapy related to
myelodysplastic syndromes and AML.14 Other authors
confirm that this rearrangement is a non-random
cytogenetic abnormality of therapy-related AML.17.IO.lJ.20.19
Around 8 percent of the children treated for ALL
develop secondary leukemia 5 to 36 months after
treatment, II and 9 out of 91 secondary AML cases studied
by PERDERSEN-BJERGAARD et al.1o showed
rearrangement of (11q23). The latency for development
of secondary leukemia was shorter when compared to
patients without abnormalities of chromosome II.
The cumulative risk of secondary AML is apparently
increased among certain groups, especially those with a
T-cell phenotype (19.1 percent at 6 years)11 and those who
received epipodophyllotoxins once or twice a week (12
percent at 6 years)Y It seems that it is the treatment
frequency, and not the leukemia cell phenotype, that is
critical in influencing the risk of secondary AML arising
during remission of ALLY Immunophenotypic studies in
the present case revealed that blast cells expressed early
pre-B and myeloid markers.
Unfortunately, as cytogenetics and immunophenotype
studies were not performed at diagnosis, we cannot affirm
what happened in relapse. We could consider the possibility
of a secondary mixed leukemia with clonal chromosome
changes of t(9: 11) (p21 :q23). if we interpret the initial
Figure 1 - Bone marrow karyotype showing 45,XY, t(9; 11)(p21; q23), -13.
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Translocations involving (11q23) are
common in acute myeloid leukemia (AML) of the
M5 FAB subtype. 15The t (9; 11) (p21 ;q23)
translocation has been associated with
characteristic clinical features, and is a superior
treatment outcome for previously untreated
pediatric AML.'7.'3.7 Although rare, this
translocation has also been seen in newly
diagnosed ALL. II It has been speculated that acute
cases of leukemia associated with abnormalities
of (11 q23) originate from a multipotential stem
cell that is capable of differentiating along
myeloid or lymphoid pathways,'S
A (11 q23) translocation was found to have
relapsed in several cases of common pre-B ALL
that had either converted to calla negative pre-B
ALL or ANLL.12 Authors have suggested the
possibility of the emergence of the pluripotent
stem cell following chemotheraputic eradication
of the original B-cell precursor line.'6
More recently, at (9; II) translocation has been
described in AML secondary to acute lymphoid
leukemia previously treated with epipodo-
phyllotoxins, etoposide and teniposide.II.IO.14This
syndrome is clinically, pathologically and
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morphology and prolonged first remission with an ALL-type
protocol as a commonly-seen childhood ALL. Previous
exposure to drugs, particularly epypodophyllotoxins, 10 could
suggest that the acute leukemia was drug induced, although
a second primary leukemia in a previously mixed case cannot
be excluded.3 Perhaps chemotherapy changed the original
clone by altering its phenotypic expression. Wf? could also
consider the case as being a mixed leukemia from the
beginning which remitted and, after discontinuation of
therapy, had a later relapse.
Notwithstanding the lack of immunophenotype and
cytogenetic studies at diagnosis, we would like to alert
. hematologists that intensive chemotherapy may be also
capable of inducing secondary or treatment-related
leukemia in children. This ought to be a concern here in
Brazil, as it is in the rest of the world.
RESUMO
Apresentamos 0 caso de uma crian9a com leucemia aguda c1assificada morfologicamente como LLA (leucemia linf6ide aguda)
FAB L1 (PAS e peroxidase negativos) que alcan90u remissao com protocolo para LLA (GBTLI). Ap6s cinco meses fora de
terapia desenvolveu uma leucemia mista (C01O, C019, C013 e C033 positivos) com transloca9ao t(9; 11 )(p21 ;q23). Como,
infelizmente, os estudos de citogenetica e imunofenotipagem nao foram realizados ao diagn6stico, pode-se considerar duas
possibilidades para a recafda: uma leucemia mista secunda ria com altera9ao cromossomica clonal ou uma leucemia mista
desde 0 infcio.
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